Actively Recruiting
Impact of GLP-1 Receptor Agonists on Dry Eye Disease in Patients With Type 2 Diabetes Mellitus and Obesity
Led by Attikon Hospital · Updated on 2026-06-02
100
Participants Needed
1
Research Sites
8 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to evaluate the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on dry eye disease in patients with type 2 diabetes mellitus and obesity. Diabetes and obesity are increasing global health concerns, and these conditions are linked to eye problems like dry eye disease, which is often underdiagnosed. The study seeks to understand how newer antidiabetic medications may influence ocular surface health by assessing tear film stability and corneal changes. The study will include two groups: 50 patients receiving GLP-1 receptor agonist therapy (Semaglutide) for overweight or obesity, with or without type 2 diabetes, and 50 control individuals matched by age, sex, and body mass index who will not receive this therapy. Participants will be observed over a period of 6 months to evaluate changes in ocular surface parameters. Participants will undergo ophthalmological assessments at two time points: before starting GLP-1 RA therapy and after 6 months. These evaluations include measuring tear film break-up time, tear meniscus height, and corneal topography. Researchers will monitor changes in these ocular parameters to better understand the impact of GLP-1 RAs on dry eye disease. The study is observational and will last at least 6 months per participant.
CONDITIONS
Brief Title
Impact of GLP-1 Receptor Agonists on Dry Eye Disease in Patients With Type 2 Diabetes Mellitus and Obesity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Patients who have not previously received GLP-1 receptor agonists
- Ability to provide informed consent for study participation
You will not qualify if you...
- Pregnant or breastfeeding patients
- History of multiple severe hypoglycemic episodes within the past two years
- Active intraocular inflammation, such as infectious conjunctivitis, keratitis, scleritis, endophthalmitis, or autoimmune uveitis
- Cataract surgery or vitrectomy within the past 6 months
- History of ketoacidosis or metabolic acidosis
- History of corneal transplantation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - At baseline (single day)
Participants undergo baseline ophthalmological assessments before starting GLP-1 receptor agonist therapy or matching control observation.
1 visit (in-person)
Duration - 6 months
Participants are observed over 6 months to evaluate changes in ocular surface and tear film parameters.
1 follow-up visit (in-person) at 6 months
Trial Site Locations
Total: 1 location
1
2nd Department of Internal Medicine, Research Institute and Diabetes Center, National and Kapodistrian University of Athens, Athens, GRC.
Athens, Greece, 12462
Actively Recruiting
Research Team
V
Vaia Lambadiari, MD, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here